Lundbeck
HLUYYDrugs in Pipeline
52
Phase 3 Programs
39
Upcoming Catalysts
2
Next Catalyst
Sep 2026
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
Escitalopram 10-20 mg
Major Depressive Disorder
Clobazam Low Dose
Epilepsy
Quetiapine
Schizophrenia
Lu AA21004
Generalized Anxiety Disorder
Risperidone
Schizophrenia
Vortioxetine 10 mg
Major Depressive Disorder
Venlafaxine extended release
Major Depressive Disorder
MK0928, gaboxadol / Duration of Treatment - 1 year
Insomnia
Aripiprazole once-monthly
Schizophrenia
Idalopirdine 60 mg
Alzheimer's Disease
Azilect®
Parkinson's Disease
Bendamustine at a dose of 100 mg/m2
Indolent Non-Hodgkin's Lymphoma
Agomelatine
Major Depressive Disorder
Vortioxetine (Lu AA21004)
Major Depressive Disorder
Lu AF82422
Multiple System Atrophy
Desmoteplase
Acute Ischemic Stroke
Adjunct brexpiprazole
Major Depression Disorder
ADT
Major Depressive Disorder
Vortioxetine 10-20 mg
Major Depressive Disorder
Sertindole
Schizophrenia
Intravenous Carbamazepine (IV CBZ)
Epilepsy
Brexpiprazole
Schizophrenia
MK0928, gaboxadol
Insomnia
Aripiprazole and aripiprazole once-monthly
Schizophrenia
Nalmefene
Alcohol Dependence
Clobazam Medium Dose
Epilepsy
Clobazam
Lennox-Gastaut Syndrome
Vortioxetine 10 mg/day
Depressive Disorder, Major
gaboxadol
Insomnia
rasagiline
Parkinson's Disease
Eptinezumab
Chronic Migraine in Children
Zicronapine
Schizophrenia
Quetiapine extended release
Schizophrenia
Vortioxetine 20 mg/day
Depressive Disorder, Major
Olanzapine
Schizophrenia
Idalopirdine
Alzheimer's Disease
Duloxetine
Major Depressive Disorder
Vortioxetine
Depressive Disorder, Major
Lu AF35700
Schizophrenia
Lu AG09222
Migraine
Lu AG13909
Congenital Adrenal Hyperplasia
MK0928, gaboxadol / Duration of Treatment 3 Weeks
Primary Insomnia
Vortioxetine (IV)
Depressive Disorder, Major
Lu AA24530
Major Depressive Disorder
vortioxetine 10 mg tablet
Attention Deficit Hyperactivity Disorder
Escitalopram 20 mg
Major Depressive Disorder
Vortioxetine infusion 25 mg
Major Depressive Disorder
Lu AA24493
Friedreich's Ataxia
Zicronapine open-label lead-in 10 mg daily
Schizophrenia
Venlafaxine XL
Major Depressive Disorder
Lu AE58054
Schizophrenia
Melperone HCl
Parkinson's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Escitalopram 10-20 mg | Phase 3 | Major Depressive Disorder | - | - |
Clobazam Low Dose | Phase 3 | Epilepsy | - | - |
Quetiapine | Phase 3 | Schizophrenia | - | - |
Lu AA21004 | Phase 3 | Generalized Anxiety Disorder | - | - |
Risperidone | Phase 3 | Schizophrenia | - | - |
Vortioxetine 10 mg | Phase 3 | Major Depressive Disorder | - | - |
Venlafaxine extended release | Phase 3 | Major Depressive Disorder | - | - |
MK0928, gaboxadol / Duration of Treatment - 1 year | Phase 3 | Insomnia | - | - |
Aripiprazole once-monthly | Phase 3 | Schizophrenia | - | - |
Idalopirdine 60 mg | Phase 3 | Alzheimer's Disease | - | - |
Azilect® | Phase 3 | Parkinson's Disease | - | - |
Bendamustine at a dose of 100 mg/m2 | Phase 3 | Indolent Non-Hodgkin's Lymphoma | - | - |
Agomelatine | Phase 3 | Major Depressive Disorder | - | - |
Vortioxetine (Lu AA21004) | Phase 3 | Major Depressive Disorder | - | - |
Lu AF82422 | Phase 3 | Multiple System Atrophy | - | - |
Desmoteplase | Phase 3 | Acute Ischemic Stroke | - | - |
Adjunct brexpiprazole | Phase 3 | Major Depression Disorder | - | - |
ADT | Phase 3 | Major Depressive Disorder | - | - |
Vortioxetine 10-20 mg | Phase 3 | Major Depressive Disorder | - | - |
Sertindole | Phase 3 | Schizophrenia | - | - |
Intravenous Carbamazepine (IV CBZ) | Phase 3 | Epilepsy | - | - |
Brexpiprazole | Phase 3 | Schizophrenia | - | - |
MK0928, gaboxadol | Phase 3 | Insomnia | - | - |
Aripiprazole and aripiprazole once-monthly | Phase 3 | Schizophrenia | - | - |
Nalmefene | Phase 3 | Alcohol Dependence | - | - |
Clobazam Medium Dose | Phase 3 | Epilepsy | - | - |
Clobazam | Phase 3 | Lennox-Gastaut Syndrome | - | - |
Vortioxetine 10 mg/day | Phase 3 | Depressive Disorder, Major | - | - |
gaboxadol | Phase 3 | Insomnia | - | - |
rasagiline | Phase 3 | Parkinson's Disease | - | - |
Eptinezumab | Phase 3 | Chronic Migraine in Children | - | - |
Zicronapine | Phase 3 | Schizophrenia | - | - |
Quetiapine extended release | Phase 3 | Schizophrenia | - | - |
Vortioxetine 20 mg/day | Phase 3 | Depressive Disorder, Major | - | - |
Olanzapine | Phase 3 | Schizophrenia | - | - |
Idalopirdine | Phase 3 | Alzheimer's Disease | - | - |
Duloxetine | Phase 3 | Major Depressive Disorder | - | - |
Vortioxetine | Phase 3 | Depressive Disorder, Major | - | - |
Lu AF35700 | Phase 3 | Schizophrenia | - | - |
Lu AG09222 | Phase 2 | Migraine | - | - |
Lu AG13909 | Phase 2 | Congenital Adrenal Hyperplasia | - | - |
MK0928, gaboxadol / Duration of Treatment 3 Weeks | Phase 2 | Primary Insomnia | - | - |
Vortioxetine (IV) | Phase 2 | Depressive Disorder, Major | - | - |
Lu AA24530 | Phase 2 | Major Depressive Disorder | - | - |
vortioxetine 10 mg tablet | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
Escitalopram 20 mg | Phase 2 | Major Depressive Disorder | - | - |
Vortioxetine infusion 25 mg | Phase 2 | Major Depressive Disorder | - | - |
Lu AA24493 | Phase 2 | Friedreich's Ataxia | - | - |
Zicronapine open-label lead-in 10 mg daily | Phase 2 | Schizophrenia | - | - |
Venlafaxine XL | Phase 2 | Major Depressive Disorder | - | - |
Lu AE58054 | Phase 2 | Schizophrenia | - | - |
Melperone HCl | Phase 2 | Parkinson's Disease | - | - |